Europe Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product (Gene Therapy, Cell Therapy, and Tissue Engineered & Others), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Country

Europe Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product (Gene Therapy, Cell Therapy, and Tissue Engineered & Others), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Country and Growth Forecast, 2022 - 2028

The Europe Advanced Therapy Medicinal Products CDMO Market would witness market growth of 16.5% CAGR during the forecast period (2022-2028).

The study of ATMPs is a field that is experiencing rapid expansion, though the majority of the developed products are still in the early stages of research. The ongoing combined trials and the possible development to treat severe chronic illnesses have led the probability of ATMPs being available on the market soon.

Targeted medicines have made it possible for there to be new trial techniques, and ATMPs could profit from these new trial methodologies to acquire early access. The majority of consumers also anticipate CDMOs to provide their knowledge in many processes even after manufacturing, such as during product launches.

This is primarily due to CDMO's growing customer base, which includes smaller biotech companies in addition to the major pharmaceutical corporations. In addition, many smaller biotech firms put a lot of effort into developing their drug pipelines without any manufacturing background. The early incorporation of smaller biotech enterprises' activities is thus made possible by using CDMOs' assistance in development and manufacturing operations.

The European Medicines Agency's Committee for Advanced Therapies (CAT) is tasked with evaluating marketing authorization (MA) requests for ATMPs and making scientific recommendations for the categorization of ATMPs, among other duties. The EMA and the European Commission released a joint action plan with the intention of streamlining procedures and better addressing the unique needs of ATMP developers. Such developments in the field of gene and cell therapy are propelling the growth of the advanced therapy medicinal products CDMO market in the coming years.

The Germany market dominated the Europe Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $749.2 million by 2028. The UK market is anticipated to grow at a CAGR of 15.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 17.3% during (2022 - 2028).

Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)

Scope of the Study

Market Segments covered in the Report:

By Indication

• Oncology
• Cardiology
• Central Nervous System & Musculoskeletal
• Infectious Disease
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

• Gene Therapy
• Cell Therapy
• Tissue Engineered & Others

• Phase I
• Phase II
• Phase III
• Phase IV

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

• Thermo Fisher Scientific, Inc. (Patheon, Inc.)
• AGC Biologics, Inc. (AGC, Inc.)
• Catalent, Inc.
• Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
• WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
• Lonza Group AG
• Celonic AG (JRS PHARMA GmbH & Co. KG)
• Rentschler Biopharma SE
• Bio Elpida (Polyplus-transfection SA.)

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free